Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18648414 | METHOD FOR EXTRACTING CHONDROITIN SULFATE FROM EGGSHELL MEMBRANE | April 2024 | June 2024 | Allow | 1 | 0 | 0 | No | No |
| 18517380 | CRYSTALLINE SOLIDS OF NICOTINIC ACID MONONUCLEOTIDE AND ESTERS THEREOF AND METHODS OF MAKING AND USE | November 2023 | February 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18320118 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGS | May 2023 | October 2023 | Allow | 5 | 1 | 1 | Yes | No |
| 18197174 | METHOD OF INDUSTRIAL EXTRACTION OF ALGINATES FROM BROWN SEAWEED OF THE FAMILY SARGASSACEAE OF THE ORDER FUCALES | May 2023 | May 2024 | Allow | 12 | 0 | 0 | No | No |
| 18141832 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | May 2023 | October 2023 | Allow | 6 | 1 | 0 | No | No |
| 18130132 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | April 2023 | July 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18129345 | CRYSTALLINE SOLIDS OF NICOTINIC ACID MONONUCLEOTIDE AND ESTERS THEREOF AND METHODS OF MAKING AND USE | March 2023 | August 2023 | Allow | 5 | 1 | 0 | No | No |
| 18115898 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | March 2023 | June 2023 | Allow | 3 | 0 | 0 | No | No |
| 18115897 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | March 2023 | May 2023 | Allow | 2 | 0 | 0 | No | No |
| 18115901 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | March 2023 | June 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 18108480 | METHODS OF PREPARING 1`-CYANO NUCLEOSIDES | February 2023 | February 2024 | Allow | 12 | 0 | 0 | No | No |
| 18099477 | CRYSTALLINE FORMS OF (S)-2-ETHYLBUTYL 2-(((S)-(((2R,3S,4R,5R)-5- (4-AMINOPYRROLO[2,1-F] [1,2,4]TRIAZIN-7-YL)-5-CYANO-3,4-DIHYDROXYTETRAHYDROFURAN-2-YL)METHOXY) (PHENOXY) PHOSPHORYL)AMINO)PROPANOATE | January 2023 | May 2024 | Allow | 15 | 1 | 0 | No | No |
| 18011614 | METHOD FOR PREPARING CRYSTALLINE D-PSICOSE | December 2022 | July 2023 | Allow | 7 | 0 | 0 | No | No |
| 18083674 | PROCESS FOR PREPARING MANNOSE DERIVATIVES | December 2022 | August 2024 | Abandon | 20 | 1 | 0 | No | No |
| 18083089 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | December 2022 | December 2023 | Allow | 12 | 0 | 0 | Yes | No |
| 18065503 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGS | December 2022 | March 2024 | Allow | 15 | 1 | 1 | No | No |
| 18074179 | Synthesis of Protected 3'-amino Nucleoside Monomers | December 2022 | August 2024 | Abandon | 20 | 1 | 0 | No | No |
| 18072260 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | November 2022 | June 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18056301 | METHOD FOR DISSOLVING SCARS WITH DEXTRAN SULFATE | November 2022 | April 2024 | Allow | 17 | 1 | 0 | No | No |
| 18052083 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | November 2022 | March 2024 | Allow | 16 | 0 | 0 | Yes | No |
| 17972041 | COMPOUNDS AND METHODS FOR ALTERING CYTO-STATES OF CELLS THAT EXPRESS C-TYPE LECTIN RECEPTORS | October 2022 | April 2024 | Allow | 18 | 3 | 1 | No | No |
| 17971194 | ASCAROSIDE DERIVATIVES AND METHODS OF USE | October 2022 | July 2023 | Allow | 9 | 1 | 1 | No | No |
| 17970080 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | October 2022 | December 2023 | Allow | 14 | 0 | 0 | Yes | No |
| 17967775 | METHOD OF PROTECTING A RESPIRATORY TRACT OR A LUNG FROM DAMAGE, METHOD OF PROTECTING A LUNG FROM PRESSURE DAMAGE INDUCED BY A VENTILATOR, METHOD OF SUPPRESSING SPREAD OF INFECTION WITH VIRUSES OR BACTERIA THAT CAUSE PNEUMONIA IN PULMONARY BRONCHIAL EPITHELIAL CELLS OR ALVEOLAR EPITHELIAL CELLS, AND NASAL SPRAY | October 2022 | January 2024 | Abandon | 15 | 1 | 1 | No | No |
| 17956774 | 2-ALKYNYLMANNOSE DERIVATIVE AND APPLICATION THEREOF | September 2022 | December 2023 | Abandon | 15 | 1 | 0 | Yes | No |
| 17946670 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | September 2022 | November 2022 | Allow | 2 | 0 | 0 | Yes | No |
| 17822679 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGS | August 2022 | April 2023 | Allow | 15 | 1 | 1 | Yes | No |
| 17896154 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | August 2022 | July 2024 | Abandon | 23 | 0 | 1 | No | No |
| 17890823 | BINDERS AND ASSOCIATED PRODUCTS | August 2022 | March 2024 | Allow | 19 | 1 | 0 | No | No |
| 17888952 | INOSITOL PHOSPHATE-CONTAINING COMPOSITION | August 2022 | September 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17888312 | SYNTHESIS OF PHOSPHATE DERIVATIVES | August 2022 | March 2024 | Allow | 19 | 1 | 0 | No | No |
| 17887060 | CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE | August 2022 | March 2024 | Allow | 19 | 1 | 0 | No | No |
| 17818931 | VACCINE AGAINST KLEBSIELLA PNEUMONIAE | August 2022 | February 2024 | Allow | 18 | 0 | 1 | Yes | No |
| 17867541 | 5`S-LNA nucleotides and oligonucleotides | July 2022 | June 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17863135 | C-TERMINAL HSP90 INHIBITORS | July 2022 | February 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 17858099 | 3' PROTECTED NUCLEOTIDES | July 2022 | May 2023 | Allow | 11 | 1 | 1 | No | No |
| 17856460 | Steviol Glycoside Compounds, Compositions For Oral Ingestion Or Use, And Method For Enhancing Steviol Glycoside Solubility | July 2022 | October 2023 | Allow | 16 | 0 | 0 | Yes | No |
| 17790191 | LIVER-TARGETING COMPOUND HAVING THYROID HORMONE RECEPTOR AGONIST CHARACTERISTICS AND PHARMACEUTICAL COMPOSITION THEREOF | June 2022 | January 2023 | Allow | 7 | 0 | 0 | No | No |
| 17845038 | CROSSLINKED POLYMERIC NETWORK AND USE THEREOF | June 2022 | October 2023 | Allow | 16 | 0 | 0 | Yes | No |
| 17786133 | FURANEONE GLYCOSIDE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | June 2022 | January 2023 | Allow | 7 | 0 | 0 | No | No |
| 17842135 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE NUCLEOSIDES | June 2022 | December 2022 | Allow | 6 | 0 | 0 | Yes | No |
| 17841241 | OLIGOSACCHARIDE C-GLYCOSIDE DERIVATIVES | June 2022 | June 2024 | Allow | 24 | 1 | 1 | Yes | No |
| 17835828 | NUCLEOTIDE PRODRUG COMPOUNDS | June 2022 | September 2022 | Allow | 4 | 0 | 0 | No | No |
| 17828573 | ALKALIZED ORGANIC PHARMACEUTICAL OR NUTRACEUTICAL COMPOSITION | May 2022 | February 2024 | Allow | 21 | 1 | 1 | Yes | No |
| 17824377 | Synthesis of Protected 3'-amino Nucleoside Monomers | May 2022 | March 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17752510 | KRILL-DERIVED CHITIN PRODUCTS AND METHODS OF MAKING SAME | May 2022 | March 2024 | Allow | 22 | 2 | 0 | Yes | No |
| 17749320 | METHOD FOR PRODUCING FUNCTIONAL CRYSTALLINE SWEETENER | May 2022 | May 2024 | Allow | 24 | 3 | 0 | No | No |
| 17745497 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | May 2022 | October 2022 | Allow | 5 | 0 | 0 | No | No |
| 17745505 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | May 2022 | October 2022 | Allow | 5 | 0 | 0 | Yes | No |
| 17745491 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | May 2022 | September 2022 | Allow | 4 | 0 | 0 | Yes | No |
| 17745516 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | May 2022 | July 2022 | Allow | 2 | 0 | 0 | Yes | No |
| 17745487 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | May 2022 | September 2022 | Allow | 4 | 0 | 0 | Yes | No |
| 17745464 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | May 2022 | July 2022 | Allow | 2 | 0 | 0 | Yes | No |
| 17745481 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | May 2022 | August 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17745470 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | May 2022 | August 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17775588 | LOW-MOLECULAR-WEIGHT HOLOTHURIAN GLYCOSAMINOGLYCAN AND USE THEREOF | May 2022 | March 2023 | Allow | 10 | 1 | 0 | No | No |
| 17662725 | USES OF PULSATILLA CHINENSIS EXTRACT IN PREPARING DRUG FOR TREATING VIRAL AND/OR BACTERIAL DISEASES | May 2022 | June 2023 | Allow | 14 | 1 | 0 | No | No |
| 17739376 | PROCESSES FOR PRODUCING PHARMACEUTICAL EXCIPIENTS FROM LIGNOCELLULOSIC BIOMASS, AND PHARMACEUTICAL EXCIPIENTS OBTAINED THEREFROM | May 2022 | December 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17734794 | SENNOSIDE MEDICATED CHEWS | May 2022 | February 2023 | Allow | 10 | 2 | 0 | No | No |
| 17728503 | HEPARIN AND HEPARAN SULPHATE OLIGOSACCHARIDES | April 2022 | August 2023 | Allow | 16 | 1 | 0 | No | No |
| 17726745 | PROCESS FOR PREPARING 3'-O-AMINO-RIBONUCLEOTIDE | April 2022 | November 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17711799 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS, NICOTINAMIDE RIBOFURANOSIDE SALTS AS SUCH, AND USES THEREOF | April 2022 | October 2022 | Allow | 6 | 1 | 0 | No | No |
| 17657021 | PURIFICATION METHOD OF FUNGAL CELL WALL COMPOSITION | March 2022 | July 2023 | Allow | 16 | 1 | 0 | No | No |
| 17656750 | ADJUVANT AND VACCINE COMPOSITIONS | March 2022 | November 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17697318 | CD73 INHIBITORS | March 2022 | June 2023 | Allow | 15 | 1 | 0 | No | No |
| 17653819 | CRYSTALLINE FORMS OF LNT | March 2022 | May 2023 | Allow | 14 | 1 | 0 | Yes | No |
| 17670779 | METHOD OF INDUSTRIAL EXTRACTION OF ALGINATES FROM BROWN SEAWEED OF THE FAMILY SARGASSACEAE OF THE ORDER FUCALES | February 2022 | April 2023 | Allow | 14 | 0 | 1 | No | No |
| 17589864 | URIDINE DIPHOSPHATE DERIVATIVES, PRODRUGS, COMPOSITIONS AND USES THEREOF | January 2022 | October 2023 | Abandon | 20 | 1 | 0 | No | No |
| 17571295 | METHODS AND COMPOSITIONS RELATING TO THE TREATMENT OF FIBROSIS | January 2022 | April 2023 | Allow | 15 | 1 | 0 | No | No |
| 17554639 | Method and Compositions for Treating Coronavirus Infection | December 2021 | June 2023 | Allow | 18 | 3 | 0 | Yes | No |
| 17612203 | METHOD FOR PREPARING HIGH-PURITY SUGAMMADEX SODIUM | November 2021 | March 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17493672 | LARGE SCALE PREPARATION OF PSEUDO-TRISACCHARIDE AMINOGLYCOSIDES AND OF INTERMEDIATES THEREOF | October 2021 | April 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17482224 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | September 2021 | November 2023 | Allow | 25 | 1 | 0 | Yes | No |
| 17472367 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | September 2021 | March 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17467918 | HyperOsmolar Composition of Hyaluronic Acid | September 2021 | February 2023 | Allow | 17 | 0 | 0 | Yes | No |
| 17405610 | MONOLITHIC COMPOSITION FOR DUAL-RATE RELEASE WITH HIGH DRUG LOADING | August 2021 | June 2023 | Allow | 22 | 0 | 1 | Yes | No |
| 17445113 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | August 2021 | May 2023 | Allow | 21 | 1 | 0 | No | No |
| 17445122 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | August 2021 | August 2023 | Allow | 24 | 1 | 1 | No | No |
| 17431103 | PROCESS FOR PREPARING 3'-O-AMINO-RIBONUCLEOTIDE | August 2021 | December 2021 | Allow | 4 | 0 | 0 | No | No |
| 17401600 | Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors | August 2021 | October 2023 | Allow | 26 | 1 | 0 | No | No |
| 17429908 | LOW-MOLECULAR-WEIGHT TREMELLA AURANTIALBA GLUCURONOXYLOMANNAN AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF | August 2021 | April 2022 | Allow | 8 | 1 | 0 | No | No |
| 17393496 | MORPHIC FORMS OF 4-AMINO-7-(3,4-DIHYDROXY-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-2-METHYL-7H-PYRROLO[2,3-d]PYRIMIDINE-5-CARBOXAMIDE AND USES THEREOF | August 2021 | October 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17392970 | SOLID FORMS OF (2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(((4AR,10AR)-7-HYDROXY-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO[G]QUINOLIN-6-YL)OXY)TETRAHYDRO-2H-PYRAN-2-CARBOXYLIC ACID | August 2021 | July 2023 | Allow | 24 | 1 | 0 | No | No |
| 17391439 | PROCESS FOR THE MANUFACTURE OF (2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(((4AR,10AR)-7-HYDROXY-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO[G]QUINOLIN-6-YL)OXY)TETRAHYDRO-2H-PYRAN-2-CARBOXYLIC ACID | August 2021 | July 2023 | Allow | 24 | 1 | 0 | Yes | No |
| 17386237 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | July 2021 | January 2023 | Allow | 18 | 0 | 0 | Yes | No |
| 17383405 | PROCESS FOR MOLNUPIRAVIR | July 2021 | March 2022 | Allow | 8 | 2 | 0 | No | No |
| 17376219 | SPHINGAN OLIGOSACCHARIDES | July 2021 | April 2023 | Allow | 21 | 0 | 1 | Yes | No |
| 17373731 | INOSITOL-STABILIZED ARGININE-SILICATE FOR HAIR GROWTH AND THICKENING | July 2021 | October 2023 | Allow | 27 | 4 | 1 | No | No |
| 17371427 | GLIFLOZINS AND A METHOD FOR THEIR DELIVERY DURING RESUSCITATION FROM CARDIAC ARREST TO IMPROVE SURVIVAL OUTCOMES | July 2021 | June 2023 | Allow | 23 | 1 | 1 | No | No |
| 17361195 | INJECTABLE MONOPHASE HYDROGELS | June 2021 | July 2024 | Abandon | 37 | 2 | 0 | No | Yes |
| 17360502 | SCUTELLARIN AMIDE DERIVATIVES, AND PREPARATION METHODS AND USES THEREOF | June 2021 | March 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17418813 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OCULAR SURFACE DISEASE | June 2021 | April 2024 | Allow | 33 | 1 | 1 | No | No |
| 17417332 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | June 2021 | January 2024 | Allow | 31 | 0 | 0 | Yes | No |
| 17416186 | 3' PROTECTED NUCLEOTIDES | June 2021 | April 2022 | Allow | 10 | 1 | 1 | Yes | No |
| 17344217 | PURIFICATION OF SULFOBUTYLATED CYCLODEXTRINS WITH SPECIFIC ION EXCHANGE RESINS | June 2021 | January 2023 | Allow | 19 | 1 | 0 | No | No |
| 17333791 | PHOSPHORIC ACID-ESTERIFIED FINE CELLULOSE FIBER AND METHOD FOR PRODUCING THE SAME | May 2021 | May 2023 | Allow | 24 | 1 | 0 | No | No |
| 17323789 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | May 2021 | December 2021 | Allow | 6 | 2 | 1 | Yes | No |
| 17319714 | COMPOUNDS AND METHODS FOR MANUFACTURE OF HYPOMETHYLATING AGENTS | May 2021 | March 2023 | Abandon | 22 | 0 | 1 | No | No |
| 17292657 | METHOD FOR DECOLORIZING AND DEPROTEINIZING BROWN ALGAE POLYSACCHARIDES | May 2021 | October 2022 | Allow | 18 | 1 | 0 | No | No |
| 17306614 | USE OF LACTULOSE IN THE TREATMENT OF AUTISM | May 2021 | July 2023 | Abandon | 26 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BERRY, LAYLA D.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 16.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BERRY, LAYLA D works in Art Unit 1623 and has examined 867 patent applications in our dataset. With an allowance rate of 61.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 25 months.
Examiner BERRY, LAYLA D's allowance rate of 61.5% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BERRY, LAYLA D receive 1.70 office actions before reaching final disposition. This places the examiner in the 48% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by BERRY, LAYLA D is 25 months. This places the examiner in the 64% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +9.2% benefit to allowance rate for applications examined by BERRY, LAYLA D. This interview benefit is in the 44% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 24.7% of applications are subsequently allowed. This success rate is in the 27% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 50.0% of cases where such amendments are filed. This entry rate is in the 69% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 40% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 57.6% of appeals filed. This is in the 26% percentile among all examiners. Of these withdrawals, 63.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 43.7% are granted (fully or in part). This grant rate is in the 47% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 1.3% of allowed cases (in the 71% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.8% of allowed cases (in the 53% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.